MPWT
MGX icon

MassMutual Private Wealth & Trust’s Metagenomi Therapeutics MGX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-593
Closed -$961 – 2514
2025
Q4 		$961 Hold
593
– – ﹤0.01% 2150
2025
Q3 		$1.41K Hold
593
– – ﹤0.01% 2077
2025
Q2 		$878 Buy
+593
New +$929 ﹤0.01% 2149

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MassMutual Private Wealth & Trust's MGX Position: Q1 2026 in Review

MassMutual Private Wealth & Trust sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 593 shares — an estimated $961 sold.

MassMutual Private Wealth & Trust first reported a position in MGX in Q2 2025 and held it in 3 quarters. The position peaked at $1.41K in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • MassMutual Private Wealth & Trust reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 593 Metagenomi Therapeutics shares in Q1 2026, an estimated $961.
  • MassMutual Private Wealth & Trust first reported a position in Metagenomi Therapeutics in Q2 2025 and held it in 3 quarters.
  • MassMutual Private Wealth & Trust's Metagenomi Therapeutics position peaked at $1.41K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q1 2026, filed 13 Apr 2026.